Catalog No.S7693

AZD6738 Chemical Structure

Molecular Weight(MW): 412.51

AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

Size Price Stock Quantity  
USD 197 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

4 Customer Reviews

  • Number of γH2AX foci per cell of irradiated (2 Gy) SAS cells treated with inhibitors against ATM (ATMi, KU55933), DNA-PK (DNA-PKi, KU57788), or ATR (ATRi, AZD6738) with or without LY364947.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1346. AZD6738 purchased from Selleck.

    Histograms showing the analysis results of RPMI8226 (transfection with control shRNA or HMGB1 shRNA) apoptosis induced by Dex (100 μM) in presence of AZD6738 (2 μM, an ATR inhibitor) (*P<0.05,**P<0.01,***P<0.001)

    J Exp Clin Cancer Res, 2018, 37(1):205. AZD6738 purchased from Selleck.

  • AZD6738 (AZD) synergizes with cytarabine (ara-C) to induce apoptosis and proliferation inhibition in AML cells. (a) OCI-AML3 cells were treated with cytarabine and AZD6738, alone or in combination, for 24 h and then subjected to annexin V-FITC/PI staining and flow cytometry analyses. CI values were calculated using CompuSyn software. Combined drug treatments were compared to single drug treatment using 1-way ANOVA with Bonferroni post hoc test. ***indicates p < 0.001. (b and c) OCI-AML3 cells were treated with cytarabine and AZD-6738, alone or in combination, for 24 h. Whole cell lysates were subjected to Western blotting and probed with the indicated antibodies.

    Sci Rep, 2017, 7:41950. AZD6738 purchased from Selleck.

    MyLa2000 cells were irradiated with UVA at dose 1.6 J/cm2. Kinase inhibitors were added at the following concentrations: 10 μM VE-821, 1 μM VE-822, 1.6 μM Chir-124, 1 μM AZD6738, 1 μM MK8776 (selected basing on toxicity studies performed previously; data not shown) 30 minutes before irradiation (30 min before UVA), immediately before irradiation (0 min before UVA) or immediately after irradiation (0 min after UVA). Cell viability was analyzed 48 hours after treatment by PI exclusion assay.

    J Dermatol Sci, 2016, 84(3):239-247. AZD6738 purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
ATR [1]
(Cell-free assay)
1 nM
In vitro

In four Kras mutant cell lines: H23, H460, A549, and H358, AZD6738 inhibits ATR kinase activity and impairs cell viability. In ATM-deficient H23 cells, AZD6738 strongly synergizes with cisplatin to induce rapid cell death. [1] In p53 or ATM defective cells, AZD6738 treatment results in replication fork stalls and accumulation of unrepaired DNA damage, resulting in cell death by mitotic catastrophe. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LICR-LON-HN4 and LICR-LON-HN5 cells MWnGeY5kfGmxbjDhd5NigQ>? M2D5[FAvODNuIECuNUwhOC5|LDCxMEA{NCBzMDFOwG0> MY\BXmQ3PzN6IHnubIljcXSrb36gc4YhSVSUIITodo92\2hibH;zd{Bw\iCmb4fud5Rz\WGvIIDoc5NxcG:{eXzheIlwdiCxZjDDTGsyKG:wIGPldlM1PS5? MmPkN|AxPTd6OUC=
K8484 cells MmrFSpVv[3Srb36gZZN{[Xl? M3HRTlIh|ryP NW\MTIZRPyCqb4Xydy=> Mn\DTY4hUzh2OESgZ4VtdHNuIFHaSFY4OzhiYYSgNkDDvU1iY3;tdIxmfGWueTDwdoV3\W62ZXSg[4Vu[2m2YXLpcoUucW6mdXPl[EBEcGtzIIDoc5NxcG:{eXzheIlwdiCxbjDT[ZJqdmViM{S1MEB1cGViZH;3cpN1emWjbTDBWHIhfGG{Z3X0Mi=> NInvVI4zQTh7MUS4PC=>
SNU-601 cells NGr0R5NE\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6 NXTUTVRLOC1zIN88cY9tN0x? M4LJ[lUh\GG7cx?= Mk\IWIhmKFNiYX7kJJN2[i2JMTDwc5B2dGG2aX;ud{Bw\iCVTmWtOlAyKGOnbHzzJJdmemViZILhcYF1cWOjbHz5JIFv\CCmb4PlMYRmeGWwZHXueIx6KGmwY4LlZZNm\CCkeTDBXmQ3PzN6Lh?= NE\aeIMzQDF|OECzOC=>
breast cancer cell lines MYjD[YxtKGe{b4f0bEBqdmirYnn0bY9vKGG|c3H5 NWTNXWZYOC5zMkWsJFAvOjVuIECuOUBidmRiMT6wJO69VQ>? M1nKV|Uh\GG7cx?= Mln1TWM2OCC4YXz1[ZMhemGwZ3XkJIZzd21iMD6zJJRwKD5zIN88cY9tN0x? NFniXoozPzVyMUGxNy=>
LoVo cells MUDGeY5kfGmxbjDhd5NigQ>? NXzUNVZkOjRiaB?= NWPYU2JyWmWmdXP0bY9vKGmwIHPlcIwh[2:3boS7JIEheHKxcH;yeIlwdiCxZjD0bIUh[2WubDDwc5B2dGG2aX;uJIFz\SBqaX6gZYRlcXSrb36geI8h[2WubDDjfYNt\SCjcoLld5QqKHWwZHXy[49qdmdiYYDvdJRwe2m|IIfo[Y4h\Xiyb4Pl[EB1dyCmcoXnJIF1KGOxbnPlcpRz[XSrb37zJIdz\WG2ZYKgeIhidiB|4pEJ{txO M2H5b|I3OzFyM{Gy

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
pCHK1 / pCDC25c / pRPA32 / γH2AX / pHH3 / cleaved caspase-3 / RAD51; 

PubMed: 29605721     

MDA-231 or Hs578t cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. After treatment, western blot was performed using anti-γH2AX, anti-pCHK1 (S345), anti-CHK1, anti-pCDC25c (S216), anti-CDC25c, anti-pHH3, anti-RAD51 anti-pRPA32 (S4/S8), anti-cleaved-caspase 3, and anti-GAPDH antibodies. 

ATM pSer1981 / ATM / ATR / Chk1 pSer345 / Chk1 / Chk2 pThr68 / Chk2; 

PubMed: 26563132     

TP53/ATM wild-type (TP53/ATM-wt) primary CLL cells cocultured with and CLL cells, both CII-GFPsh and CII-ATMsh were treated with AZD6738 (1 μM) for 2 hours, or left untreated, prior to exposure to HU (1 mM) or IR (6 Gy) for a further 5 hours. AZD6738 treatment inhibited ATR signaling as indicated by a reduction in HU-induced Chk1 phosphorylation (lanes 3 vs 4 and 9 vs 10). In ATM-proficient CLL cells, this also led to ATM activation as evidenced by ATM phosphorylation and Chk2 phosphorylation (lane 3 vs 4). 

29605721 26563132
γH2AX / RAD51; 

PubMed: 29605721     

MDA-231 cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. Cells were probed with anti-γH2AX and anti-RAD51 antibodies. Scale bar: 5 μm. 


PubMed: 26563132     

Cells treated with AZD6738 (1 μM) for 48 hours were labeled with anti-53BP1 antibodies, and at least 200 cells were then analyzed in each sample using a ×60 lens. AZD6738 treatment led to an accumulation of 53BP1 foci in Mec1 and ATMi pretreated CII cells and an accumulation of 53BP1 bodies in CII cells without ATMi pretreatment.

29605721 26563132
Growth inhibition assay
Cell viability; 

PubMed: 26563132     

CII-GFPsh, CII-ATMsh (ATM-deficient), and Mec1 (p53-defective) cells were treated with AZD6738 for 4 days, and viability was measured using the CellTiter-Glo assay. Surviving fraction is expressed relative to untreated controls. AZD6738 induced significantly greater dose-dependent cytotoxicity with significantly lower AZD6738 EC50 in CII-ATMsh and Mec1 cells compared with CII-GFPsh cells.


PubMed: 28062704     

Cell line IC50 values assessed for growth inhibition in a 72-hour MTT assay

26563132 28062704
In vivo In nude mice bearing H460 and H23 tumors, AZD6738 (50 mg/kg, p.o.) results in tumor growth inhibition (TGI), and the the combination with cisplatin causes rapid regression of ATM-deficient H23 tumors. [1] In nude mice bearing LoVo xenografts, a combination of AZD6738 (50 mg/kg) + IR (2 Gy) avoids toxicity while still maintaining efficacy. [3]


Cell Research:[1]
+ Expand
  • Cell lines: H23, H460, A549, and H358 cells
  • Concentrations: ~30 μM
  • Incubation Time: 48 h
  • Method: Cells are treated in white walled, clear bottom 96-well plates with the indicated doses of AZD6738, cisplatin, gemcitabine, or combination for 48 h. ATP levels are assessed as surrogate measure of viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay and Safire2 plate reader. Raw data are corrected for background luminescence prior to further analysis. For AZD6738 treatment, log dose response curves are generated in GraphPad Prism 6 by nonlinear regression (log(inhibitor) vs. response with variable slope) of log-transformed (x = log(x)) data normalized to the mean of untreated controls. GI50 values, defined as the dose X at which Y = 50%, were extrapolated from dose response curves.
    (Only for Reference)
Animal Research: [1]
+ Expand
  • Animal Models: Female athymic nude mice bearing H23 or H460 xenografts
  • Formulation: 10% DMSO, 40% propylene glycol, and 50% sterile dH2O
  • Dosages: 25 or 50 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (198.78 mM)
Ethanol 41 mg/mL warmed (99.39 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% propylene glycol+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 412.51


CAS No. 1352226-88-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03669601 Not yet recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust September 30 2019 Phase 1
NCT03770429 Recruiting Drug: AZD6738 Leukemia|Myelodysplastic Syndrome Massachusetts General Hospital|AstraZeneca August 5 2019 Phase 1
NCT02630199 Recruiting Drug: AZD6738|Drug: Paclitaxel Refractory Cancer Samsung Medical Center December 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

Related ATM/ATR Products

Tags: buy AZD6738 | AZD6738 supplier | purchase AZD6738 | AZD6738 cost | AZD6738 manufacturer | order AZD6738 | AZD6738 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID